Literature DB >> 32378012

Naloxone Prescribing Among Frequent Opioid Prescribers in Medicare Part D from 2013 to 2017: a Retrospective Study.

Andrew W Roberts1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32378012      PMCID： PMC7878639          DOI： 10.1007/s11606-020-05872-5

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  4 in total

1.  Naloxone Co-prescribing to Patients Receiving Prescription Opioids in the Medicare Part D Program, United States, 2016-2017.

Authors:  Christopher M Jones; Wilson Compton; Meena Vythilingam; Brett Giroir
Journal:  JAMA       Date:  2019-08-06       Impact factor: 56.272

2.  Characteristics of New Opioid Use Among Medicare Beneficiaries: Identifying High-Risk Patterns.

Authors:  Sudha R Raman; Christopher Bush; Ruchir N Karmali; Lawrence H Greenblatt; Andrew W Roberts; Asheley C Skinner
Journal:  J Manag Care Spec Pharm       Date:  2019-09

3.  Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.

Authors:  Gery P Guy; Tamara M Haegerich; Mary E Evans; Jan L Losby; Randall Young; Christopher M Jones
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-08-09       Impact factor: 17.586

4.  Association of Disability With Mortality From Opioid Overdose Among US Medicare Adults.

Authors:  Yong-Fang Kuo; Mukaila A Raji; James S Goodwin
Journal:  JAMA Netw Open       Date:  2019-11-01
  4 in total
  2 in total

1.  Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.

Authors:  Bradley D Stein; Christopher M Jones; Rosanna Smart; Flora Sheng; Mark Sorbero
Journal:  Drug Alcohol Depend       Date:  2021-02-03       Impact factor: 4.492

2.  Individual and Community Factors Associated with Naloxone Co-prescribing Among Long-term Opioid Patients: a Retrospective Analysis.

Authors:  Bradley D Stein; Rosanna Smart; Christopher M Jones; Flora Sheng; David Powell; Mark Sorbero
Journal:  J Gen Intern Med       Date:  2021-02-17       Impact factor: 6.473
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.